HubSpot to report Q2 results after market close, host conference callPUBT·Jul 22 at 03:05 PMHUBS+7.83%
Halozyme and Incyte sign licence agreement for INCA033989 formulationsPharmaceutical Business Review·Jul 21 at 04:15 AMINCY+0.84%HALO+1.35%
Halozyme partners with Incyte on ENHANZE subcutaneous formulation for INCA033989 antibodyPUBT·Jul 20 at 07:05 AMINCY+0.84%HALO+1.35%
Halozyme Therapeutics (HALO) Gets A Lift As Darzalex Faspro Trial Improves SurvivalSimplywall·Jul 18 at 04:08 AMHALO+1.35%
25,822 Shares in Halozyme Therapeutics, Inc. $HALO Acquired by Citizens Financial Group Inc. RIMarket Beat·Jul 14 at 02:38 AMHALO+1.35%
Hsbc Holdings PLC Grows Stock Holdings in Halozyme Therapeutics, Inc. $HALOMarket Beat·Jul 10 at 02:29 AMHALO+1.35%HSBA
Halozyme Therapeutics, Inc. Stock 12‑Month Price Target Cut to $83.44, Implies 6% UpsideTradingView·Jul 10 at 02:20 AMHALO+1.35%
Halozyme CEO Helen Torley disposes of 1,923 common shares worth $146,852.55PUBT·Jul 9 at 04:20 PMHALO+1.35%
Halozyme director Bernadette Connaughton sells 1,625 shares worth $124,370.63PUBT·Jul 2 at 03:43 PMHALO+1.35%
Halozyme COO Cortney Caudill departs amid senior management restructurePUBT·Jul 2 at 03:11 PMHALO+1.35%
Assenagon Asset Management S.A. Has $1.38 Million Holdings in Halozyme Therapeutics, Inc. $HALOMarket Beat·Jul 2 at 02:05 AMHALO+1.35%
